Athea Vichas

Dr. Athea Vichas is a Senior Principal Scientist at Bristol Meyer Squibb in the Cell Therapy Development Organization. Since 2021, she has led the Sequencing Analytics for Gene Editing (SAGE) group focused on developing novel NGS-based assays to characterize genomic integrity in autologous and allogeneic, genome modified CAR T products. Prior to BMS, Athea was a post-doctoral fellow at the Fred Hutchinson Cancer Research Center, where she utilized functional genomics and pooled CRISPR-based screening methods to identify novel therapeutic targets in lung adenocarcinoma. Athea earned her PhD in Molecular Genetics from The Weill Cornell Medical College and BS in Biochemistry from University of Oregon.